Capricor Posts $40.7M Q2 Loss, Faces HOPE-3 Breach Suit
CAPR has more than doubled off its 52-week low of $2.96 on elevated volume (5.4× avg).
Summary
Capricor reported a Q2 net loss of $40.7M with zero revenue, and cash fell to $237.9M from $318.1M. The company also faces a lawsuit alleging it breached blinding and protocol in the HOPE-3 trial, deviated from its statistical analysis plan, and created an SAP one day before data unblinding. This follows the FDA advisory committee's 9-3 vote against deramiocel's effectiveness data and a securities fraud class action filed earlier this month. The breach suit directly challenges the integrity of the pivotal trial data underpinning the upcoming PDUFA decision on August 22, 2026. With shares already down 85.5% YTD, the legal risk compounds the regulatory uncertainty.
At the time of this announcement, CAPR was trading at $7.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $243.8M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.